Sutro Biopharma/STRO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Sutro Biopharma

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.

Ticker

STRO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

William Newell

Employees

300

Headquarters

South san francisco, United States

Sutro Biopharma Metrics

BasicAdvanced
$346M
Market cap
-
P/E ratio
-$1.89
EPS
1.24
Beta
-
Dividend rate
$346M
1.24403
$6.13
$2.01
1M
4.46
-30.20%
-81.12%
-36.94%
2.243
2.692
3.525
106.66%
20.76%
53.24%

What the Analysts think about Sutro Biopharma

Analyst Ratings

Majority rating from 11 analysts.
Buy

Sutro Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-447.69% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$13M
-88.57%
Net income
-$58M
-287.74%
Profit margin
-447.69%
-1,742.30%

Sutro Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.04%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.64
-$0.81
$0.52
-$0.95
-
Expected
-$0.73
-$0.74
-$0.82
-$0.92
-$0.79
Surprise
-12.63%
10.05%
-163.16%
3.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sutro Biopharma stock?

Sutro Biopharma (STRO) has a market cap of $346M as of June 19, 2024.

What is the P/E ratio for Sutro Biopharma stock?

The price to earnings (P/E) ratio for Sutro Biopharma (STRO) stock is 0 as of June 19, 2024.

Does Sutro Biopharma stock pay dividends?

No, Sutro Biopharma (STRO) stock does not pay dividends to its shareholders as of June 19, 2024.

When is the next Sutro Biopharma dividend payment date?

Sutro Biopharma (STRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Sutro Biopharma?

Sutro Biopharma (STRO) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Sutro Biopharma stock price target?

The target price for Sutro Biopharma (STRO) stock is $12.3, which is NaN% below the current price of $. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Sutro Biopharma stock

Buy or sell Sutro Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing